MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer

Cellular Physiology and Biochemistry

Volumn 37, Issue 5, 2015, Pages 1869-1880

  Chen, Ying ^a   Gao, Yanping ^a   Zhang, Kai ^a   Li, Chen ^a   Pan, Yan ^a   Chen, Jing ^a   Wang, Rui ^a   Chen, Longbang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Chemo resistance; Cisplatin; Lung cancer; MicroRNA; Post transcriptional regulation

Indexed keywords

CISPLATIN; MICRORNA; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN, HUMAN;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL SURVIVAL; DRUG TARGETING; DRUG TRANSPORT; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; LUNG CANCER; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RNA PROCESSING; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LUNG NEOPLASMS; MICRORNAS;

EID: 84948179257     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000438548     Document Type: Review

References (73)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Miller YE: Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol 2005;33:216-223.
3. Artal Cortes A, Calera Urquizu L, Hernando Cubero J: Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res 2015;4:191-197.
4. Kalemkerian GP: Advances in pharmacotherapy of small cell lung cancer. Expert Opin Pharmacother 2014;15:2385-2396.
5. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279.
6. O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, Barr MP: The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treat Rev 2014;40:1161-1170.
7. Zhang B, Zhang K, Liu Z, Hao F, Wang M, Li X, Yin Z, Liang H: Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro. Cell Physiol Biochem 2014;33:1162-1175.
8. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene 2012;31:1869-1883.
9. MacDonagh L, Gray SG, Finn SP, Cuffe S, O'Byrne KJ, Barr MP: The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treat Rev 2015;41:160-169.
10. Sarkar FH, Li Y, Wang Z, Kong D, Ali S: Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010;13:57-66.
11. Wan L, Zhu L, Xu J, Lu B, Yang Y, Liu F, Wang Z: MicroRNA-409-3p functions as a tumor suppressor in human lung adenocarcinoma by targeting c-Met. Cell Physiol Biochem 2014;34:1273-1290.
12. Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, Qin X, Wang H, Wang S, Su J, Lv X, Liu H, Du W, Zhou W, Chen X, Fei K: MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem 2013;31:56-65.
13. Wu N, Zhang C, Bai C, Han YP, Li Q: MiR-4782-3p inhibited non-small cell lung cancer growth via USP14. Cell Physiol Biochem 2014;33:457-467.
14. Zhang L, Qian J, Qiang Y, Huang H, Wang C, Li D, Xu B: Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro. Cell Physiol Biochem 2014;33:1162-1175.
15. Wang J, Yang B, Han L, Li X, Tao H, Zhang S, Hu Y: Demethylation of miR-9-3 and miR-193a genes suppresses proliferation and promotes apoptosis in non-small cell lung cancer cell lines. Cell Physiol Biochem 2013;32:1707-1719.
16. Xia Y, Chen Q, Zhong Z, Xu C, Wu C, Liu B, Chen Y: Down-regulation of miR-30c promotes the invasion of non-small cell lung cancer by targeting MTA1. Cell Physiol Biochem 2013;32:476-485.
17. Lujambio A, Lowe SW: The microcosmos of cancer. Nature 2012;482:347-355.
18. Heo JI, Oh SJ, Kho YJ, Kim JH, Kang HJ, Park SH, Kim HS, Shin JY, Kim MJ, Kim M, Kim SC, Park JB, Kim J, Lee JY: ATM mediates interdependent activation of p53 and ERK through formation of a ternary complex with p-p53 and p-ERK in response to DNA damage. Mol Biol Rep 2012;39:8007-8014.
19. Cheng Q, Chen J: Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle 2010;9:472-478.
20. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26:745-752.
21. Wang X, Dong K, Gao P, Long M, Lin F, Weng Y, Ouyang Y, Ren J, Zhang H: microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status. Cancer Biother Radiopharm 2013;28:45-50.
22. Yamakuchi M, Ferlito M, Lowenstein CJ: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008;105:13421-13426.
23. Skrzypski M, Dziadziuszko R, Jassem J: MicroRNA in lung cancer diagnostics and treatment. Mutat Res 2011;717:25-31.
24. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G: MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012;19:1038-1048.
25. Cao JX, Li SY, An GS, Mao ZB, Jia HT, Ni JH: E2F1-regulated DROSHA promotes miR-630 biosynthesis in cisplatin-exposed cancer cells. Biochem Biophys Res Commun 2014;450:470-475.
26. Cao JX, Lu Y, Qi JJ, An GS, Mao ZB, Jia HT, Li SY, Ni JH: MiR-630 inhibits proliferation by targeting CDC7 kinase, but maintains the apoptotic balance by targeting multiple modulators in human lung cancer A549 cells. Cell Death Dis 2014;5:e1426.
27. Hwang HC, Clurman BE: Cyclin E in normal and neoplastic cell cycles. Oncogene 2005;24:2776-2786.
28. Zhao Z, Liu J, Wang C, Wang Y, Jiang Y, Guo M: MicroRNA-25 regulates small cell lung cancer cell development and cell cycle through cyclin E2. INT J Clin Exp Pathol 2014;7:7726-7734.
29. Bar J, Gorn-Hondermann I, Moretto P, Perkins TJ, Niknejad N, Stewart DJ, Goss GD, Dimitroulakos J: miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma. Clin Lung Cancer 2015;16:e121-129.
30. Zhang S, Zhang C, Li Y, Wang P, Yue Z, Xie S: miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. Biomed Pharmacother 2011;65:436-442.
31. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-74955.
32. Smith FM, Stephens RB, Kennedy MJ, Reynolds JV: P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92:1813.
33. Wang H, Zhu LJ, Yang YC, Wang ZX, Wang R: MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G(1)/S transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer 2014;111:339-354.
34. Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-142.
35. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010;8:1207-1216.
36. Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L, Huang H, Li S, Zhao J: MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC. PLoS One 2014;9:e94639.
37. Yu G, Chen G, Huang B, Wu S: Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells. Tumour Biol 2014;35:10341-10349.
38. Zhao Z, Zhang L, Yao Q, Tao Z: miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells. Cancer Gene Ther 2015;22:108-114.
39. Li J WY, Song Y, Fu Z, Yu W: miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol Cancer 2014;13:193.
40. Zhang F, Li Y, Zhou Q: Advances in the relationship between microRNA and cisplatin resistance of lung cancer. Zhongguo Fei Ai Za Zhi 2014;17:269-272.
41. Demirel O, Bangert I, Tampe R, Abele R: Tuning the cellular trafficking of the lysosomal peptide transporter TAPL by its N-terminal domain. Traffic 2010;11:383-393.
42. Dong Z, Zhong Z, Yang L, Wang S, Gong Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett 2014;343:249-257.
43. Zhan M, Qu Q, Wang G, Zhou H: Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL. Pharmazie 2013;68:955-961.
44. Sun W, Ma Y, Chen P, Wang D: MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-beta/Smad2/STAT3/STAT5 pathway. Mol Med Rep 2015;11:3854-3859.
45. Ma Y, Li X, Cheng S, Wei W, Li Y: MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1. Mol Med Rep 2015;11:625-632.
46. Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y: Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010;46:1692-1702.
47. Song L, Li Y, Li W, Wu S, Li Z: miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem 2014;115:1234-1242.
48. Ali S, Ali S: Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene 2007;401:38-45.
49. Li P, Ma L, Zhang Y, Ji F, Jin F: MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer cell proliferation. Biomed Pharmacother 2014;68:7-12.
50. Pan B, Chen Y, Song H, Xu Y, Wang R, Chen L: Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A. Oncotarget 2015;6:317-331.
51. Zhou L, Qiu T, Xu J, Wang T, Wang J, Zhou X, Huang Z, Zhu W, Shu Y, Liu P: miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res 2013;19:677-683.
52. Youle RJ, Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
53. Akiyama T, Dass CR, Choong PF: Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 2009;8:3173-3180.
54. Zhang F, Li Y, Wu H, Qi K, You J, Li X, Zu L, Pan Z, Wang Y, Li Y, Li Y, Wang M, Shen W, Zhou Q: MiR-192 confers cisplatin resistance by targeting Bim in lung cancer. Zhongguo Fei Ai Za Zhi 2014;17:384-390.
55. Liu L, Bian K: Advance in studies on molecular mechanisms of cisplatin resistance and intervention with traditional Chinese medicines. Zhongguo Zhong Yao Za Zhi 2014;39:3216-3220.
56. Zang YS, Zhong YF, Fang Z, Li B, An J: MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther 2012;19:773-778.
57. Qiu T, Zhou L, Wang T, Xu J, Wang J, Chen W, Zhou X, Huang Z, Zhu W, Shu Y, Liu P: miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Int J Mol Med 2013;32:593-598.
58. Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, Shu Y, Liu P: miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012;29:384-391.
59. Wang Q, Shi S, He W, Padilla MT, Zhang L, Wang X, Zhang B, Lin Y: Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition. Oncotarget 2014;5:1304-1314.
60. Li Y, Li L, Guan Y, Liu X, Meng Q, Guo Q: MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Biochem Biophys Res Commun 2013;440:604-610.
61. Xu L, Huang Y, Chen D, He J, Zhu W, Zhang Y, Liu X: Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer. Cancer Genet 2014;207:214-220.
62. Tian Z1, Yao G, Song H, Zhou Y, Geng J: IGF2R expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. Cell Physiol Biochem 2014;34:1578-1588.
63. Xu W, Hang M, Yuan CY, Wu FL, Chen SB, Xue K: MicroRNA-139-5p inhibits cell proliferation and invasion by targeting insulin-like growth factor 1 receptor in human non-small cell lung cancer.Int J Clin Exp Pathol 2015;8:3864-3870.
64. Ning FL WF, Li ML, Yu ZS, Hao YZ, Chen SS: MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. Diagn Pathol 2014;9:143.
65. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D, Fukunaka Y, Yasuniwa Y, Naito S, Nishizawa S, Sasaguri Y, Kohno K:Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth.Cancer Res 2009;69:3148-3156.
66. O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, Barr MP:The role of DNA repair pathways in cisplatin resistant lung cancer.Cancer Treat Rev 2014;40:1161-1170.
67. Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L: Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011;37:427-434.
68. Sui C, Meng F, Li Y, Jiang Y: miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1 (DNMT1) expression. J Transl Med 2015;13:132.
69. Zhou DH, WX, Feng Q: EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells. Nutr Cancer 2014;66:636-644.
70. Hu X, Zhang F, Liu XR, Wu YT, Ni YM: Efficacy and potential microRNA mechanism for computed tomography-guided percutaneous radiofrequency ablation of primary lung cancer and lung metastasis from liver cancer. Cell Physiol Biochem 2014;33:1261-1271.
71. Guo J, Feng Z, Huang Z, Wang H, Lu W: MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer. Mol Cells 2014;37:664-671.
72. Li N, Zhang F, Li S, Zhou S: Epigenetic silencing of MicroRNA-503 regulates FANCA expression in non-small cell lung cancer cell. Biochem Biophys Res Commun 2014;444:611-616.
73. Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y: MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012;13:330-340.